Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P4HB | P07237 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 2/20 | 0.43 |
| ▸ | MAOB | P27338 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | GMNN | O75496 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11855729 | 0.86 | P4HB (0.45) | P4HBMAOAMAOBTSHRBACE1 | |
| SCHEMBL6068906 | 0.82 | P4HB (0.43) | P4HBMAOAMAOBTSHRBACE1 | |
| SCHEMBL78524 | 0.82 | TSHR (0.46) | P4HBMAOAMAOBTSHRBACE1 | |
| SCHEMBL6068909 | 0.82 | P4HB (0.43) | P4HBMAOAMAOBTSHRBACE1 | |
| SCHEMBL79094 | 0.80 | TSHR (0.42) | P4HBMAOAMAOBTSHRBACE1 | |
| SCHEMBL3802466 | 0.77 | KMT2A (0.52) | MAOAMAOBRAB9ASMN1; SMN2ALOX15 | |
| SCHEMBL29296553 | 0.77 | ALDH1A1 (0.49) | MAOAMAOBTSHRBACE1RAB9A | |
| SCHEMBL8444002 | 0.76 | P4HB (0.41) | P4HBMAOAMAOBTSHRBACE1 | |
| SCHEMBL23409911 | 0.76 | P4HB (0.38) | P4HBMAOAMAOBBACE1SMN1; SMN2 | |
| SCHEMBL1128730 | 0.76 | P4HB (0.42) | P4HBTSHRRAB9ASMN1; SMN2ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238305-A1 | FORMULATIONS OF 3-((3-(4-(2-(ISOBUTYLSULFONYL)PHENOXY)-3-(TRIFLUOROMETHYL)PHENYL)-1,2,4-OXADIAZOL-5-YL)METHYL)-5,5-DIMETHYL-1-(2-MORPHOLINOETHYL)IMIDAZOLIDINE-2,4-DIONE | NOVARTIS AG (CH) | 2024-07-18 | — | — | US | disclosed |
| US-20240238305-A1 | FORMULATIONS OF 3-((3-(4-(2-(ISOBUTYLSULFONYL)PHENOXY)-3-(TRIFLUOROMETHYL)PHENYL)-1,2,4-OXADIAZOL-5-YL)METHYL)-5,5-DIMETHYL-1-(2-MORPHOLINOETHYL)IMIDAZOLIDINE-2,4-DIONE | NOVARTIS AG (CH) | 2024-07-18 | — | — | US | disclosed |
| US-20240238305-A1 | FORMULATIONS OF 3-((3-(4-(2-(ISOBUTYLSULFONYL)PHENOXY)-3-(TRIFLUOROMETHYL)PHENYL)-1,2,4-OXADIAZOL-5-YL)METHYL)-5,5-DIMETHYL-1-(2-MORPHOLINOETHYL)IMIDAZOLIDINE-2,4-DIONE | NOVARTIS AG (CH) | 2024-07-18 | — | — | US | disclosed |
| EP-4340808-A1 | FORMULATIONS OF 3-((3-(4-(2-(ISOBUTYLSULFONYL)PHENOXY)-3-(TRIFLUOROMETHYL)PHENYL)-1,2,4-OXADIAZOL-5-YL)METHYL)-5,5-DIMETHYL-1-(2-MORPHOLINOETHYL)IMIDAZOLIDINE-2,4-DIONE | Novartis AG (CH) | 2024-03-27 | — | — | EP | disclosed |
| CN-117729911-A | Formulation of 3- ((3- (4- (2- (isobutylsulfonyl) phenoxy) -3- (trifluoromethyl) phenyl) -1,2, 4-oxadiazol-5-yl) methyl) -5, 5-dimethyl-1- (2-morpholinoethyl) imidazolidine-2, 4-dione | 诺华股份有限公司 | 2024-03-19 | — | — | CN | disclosed |
| WO-2022249006-A1 | USE OF 1,2,4-OXADIAZOLE DERIVATIVES AS LIVER X RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2022-12-01 | — | — | WO | disclosed |
| US-20220340573-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AS LIVER X RECEPTOR AGONISTS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2022-10-27 | — | — | US | disclosed |
| EP-4065228-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AS LIVER X RECEPTOR AGONISTS | Novartis AG (CH) | 2022-10-05 | — | — | EP | disclosed |
| US-11427586-B2 | 1,2,4-oxadiazole derivatives as liver X receptor agonists | NOVARTIS AG (CH) | 2022-08-30 | — | — | US | disclosed |
| CN-114746149-A | 1,2, 4-oxadiazole derivatives as liver X receptor agonists | 诺华股份有限公司 | 2022-07-12 | — | — | CN | disclosed |
| US-20220064164-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AS LIVER X RECEPTOR AGONISTS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2022-03-03 | — | — | US | disclosed |
| WO-2021105857-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AS LIVER X RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2021-06-03 | — | — | WO | disclosed |
| US-20180134667-A1 | INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE | TES PHARMA S.R.L. (IT) | 2018-05-17 | — | — | US | disclosed |
| WO-2018069532-A1 | INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE | TES PHARMA S.R.L. (IT) | 2018-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220064164-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AS LIVER X RECEPTOR AGONISTS | NR1H4, GPBAR1, NR1I2 | P4HB 1354/4885MAOA 1307/4885MAOB 1267/4885 |
| US-20240238305-A1 | FORMULATIONS OF 3-((3-(4-(2-(ISOBUTYLSULFONYL)PHENOXY)-3-(TRIFLUOROMETHYL)PHENYL)-1,2,4-OXADIAZOL-5-YL)METHYL)-5,5-DIMETHYL-1-(2-MORPHOLINOETHYL)IMIDAZOLIDINE-2,4-DIONE | MGST1, MGAT3, DMPK | P4HB 732/4885MAOA 2532/4885MAOB 1979/4885 |
| US-20180134667-A1 | INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE | ACMSD, GLS, ALDH7A1 | P4HB 3177/4885MAOA 181/4885MAOB 259/4885 |
| US-11427586-B2 | 1,2,4-oxadiazole derivatives as liver X receptor agonists | NR1H4, GPBAR1, NR1I2 | P4HB 1354/4885MAOA 1307/4885MAOB 1267/4885 |
| US-20220340573-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AS LIVER X RECEPTOR AGONISTS | NR1H4, GPBAR1, NR1I2 | P4HB 1354/4885MAOA 1307/4885MAOB 1267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.